Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Avensia: November sales on the softer side, yet margins should be stable - Redeye

Analys | Redeye

•

Idag 13:33

Avensia: November sales on the softer side, yet margins should be stable - Redeye

AAC Clyde Space: Directed Unit Issue to Bonner Capital - Redeye

Redeye is encouraged by AAC’s announcement this morning, where Bonnier Capital, through a directed i...

Gofore: Becomes founding partner in AI-focused venture - SEB

Truecaller: Preliminary Q4 revenue figures significantly missed our estimates - Redeye

Redeye briefly comments on Truecaller releasing an update regarding its Q4 2025 revenue development,...

Aktia Bank: Looking for continued delivery - SEB

G5 Entertainment: An interesting setup heading into 2026 - SEB

We expect Q4 to show continued positive momentum, supported by recent trends in key franchises and a...

Gapwaves: Hella’s major win likely involves Gapwaves - Redeye

Gapwaves

Analys | Research feed

•

12 Dec 11:17

Xintela: Extending the financial runway - VH Corp

* The rights issue added MSEK 42 before loan offset * Fenja Capital II provides loan facility of MSE...

Nanexa: First license with Moderna an important validation of PharmaShell - Emergers

Smart Eye: Financing Locked In - Redeye

Smart Eye has successfully issued a SEK300m senior unsecured bond at 3M STIBOR + 7%, which we view a...

Smart Eye

Analys | ABG Sundal Collier

•

12 Dec 07:24

Careium: Downgrades '25e outlook - ABG

Careium adjusts FY 2025 result - SEB

Due to longer sales cycles in the UK and Germany, Careium announced its full-year 2025 guidance will...

Optomed: Directed share issue announcement - Redeye

Inderes: Strong CMD season backs clear beat in November - SEB

Inderes delivered solid monthly sales in November with sales increasing by 15% y/y.

Inderes

Analys | Analysguiden

•

11 Dec 10:28

Railcare Group: Rekordkvartal - Analysguiden

Active Biotech: Subscription Rate 83% - Redeye

Redeye comments on the subscription rate in Active Biotech's rights issue.

Gapwaves: Funded to scale, setting sail - Redeye

Lytix: Solid Runway For Verrica - Redeye

We raise our base case after having evaluated the financial situation of Verrica, which raised USD50...

Lytix Biopharma

Analys | Analysguiden

•

10 Dec 10:42

Systemair: Efter andra kvartalet - Analysguiden

Systemair

Analys | ABG Sundal Collier

•

10 Dec 09:08

OssDsign: New CEO appointed - ABG

* Mark Waugh appointed new CEO * Relevant background from orthapaedic industry * Supportive for sent...

OssDsign: Appoints Mark Waugh as new CEO - SEB

Gofore: November data shows positive signs in organic performance - SEB

Gofore's November sales lagged slightly behind our estimate, as in October.

Senzime: Solid order from the UK - Redeye

OXE Marine: Securing loans of SEK49m - Redeye

OXE Marine has signed a new financing agreement securing a total of SEK49m to facilitate the transfe...

Surgical Science: More realistic targets, will need to regain investor confidence - Redeye

Surgical Science

Analys | Research feed

•

09 Dec 07:21

aXichem: Nytt avrop från Chr. Olesen - VH Corp

* Ny levereans till Chr. Olesen inom ramen för avropsordern * Ordern motsvarar cirka 2,6 MSEK * Kort...

BioInvent: Another Strong Readout with BI-1206 - Redeye

Acarix: SEK33.4m directed share issue - Redeye

Redeye comments on today's announcement that Acarix has carried out a directed share issue of approx...

Cinclus Pharma: Secured reimbursement in China - Redeye

Smart Eye: Moves to Secure Long-Term Funding - Redeye

Redeye comments on Smart Eye exploring the issuance of a SEK300m senior unsecured bond.

Smart Eye

Föregående Nästa